Overview

Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Different types of stem cells have recently been studied in clinical trial on ischemic disease of the heart and muscular arteries. Adipose derived stem cell, have shown in vitro and in vivo models a stronger potential of success in recovering from ischemic disease and oxygenation of the tissues. The investigators already shown in a phase I study, that adipose derived mesenchymal cells injected in patients with critical limb ischemia and no option for revascularization, had a very good tolerance and interesting effects on skin oxygenation and healing. The aim of the present clinical trial is to confirm the efficacy autologous transplantation of adipose tissue derived mesenchymal cells in patients with critical limb ischemia with poor options or no option for revascularization.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Toulouse
Collaborators:
Etablissement Français du Sang
Institut National de la Santé Et de la Recherche Médicale, France